The safety of infliximab infusions in the community setting

Canadian Journal of Gastroenterology

Volumn 24, Issue 5, 2010, Pages 307-311

  Ducharme, James ^a   Pelletier, Cindy ^b   Zacharias, Ramesh ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b AIM Health Group   (Canada)

^c Centres for Pain Management   (Canada)

Author keywords

Adverse events; Community setting; Infliximab; Safety

Indexed keywords

ADRENALIN; DIPHENHYDRAMINE; HYDROCORTISONE; INFLIXIMAB; METHYLPREDNISOLONE; PARACETAMOL; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTICLE; CHILD; COMMUNITY CARE; COST BENEFIT ANALYSIS; CROHN DISEASE; DIAPHORESIS; DIZZINESS; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSPNEA; EMERGENCY HEALTH SERVICE; FEMALE; FLU LIKE SYNDROME; FLUSHING; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; JOINT STIFFNESS; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RASH; REMISSION; RHEUMATOID ARTHRITIS; RIGOR; SCHOOL CHILD; SIDE EFFECT; STRIDOR; TEMPERATURE; THORAX PAIN; ULCERATIVE COLITIS; URTICARIA; WHEEZING;

EID: 77952315364     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2010/138456     Document Type: Article

References (17)

1. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
2. Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheum 2005;52:3381-3390
3. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor-alpha: Monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-1563
4. Reimund JM, Wittersheim C, Dumont S, et al. Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996;39:684-689 (Pubitemid 26426469)
5. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009;136:1182-1197
6. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997;349:521-524
7. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005;72:250-256 (Pubitemid 41052052)
8. Leman JA, Burden AD. Treatment of severe psoriasis with infliximab. Ther Clin Risk Manag 2008;4:1165-1175
9. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokines 1995;7:251-259
10. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-155 (Pubitemid 36278124)
11. Lees CW, Ali AI, Thompson AI, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: Analysis of 620 patient-years follow-up. Aliment Pharmacol Ther 2009;29:286-297
12. Listing J, Strangfeld A, Kekow J, et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 2008;58:667-677
13. Menter A, Reich K, Gottlieb AB, et al. Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations. J Drugs Dermatol 2008;7:1137-1146
14. Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009;60:1001-1017
15. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359:1541.
16. Colombel J, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients. Gastroenterology 2004;126:19-31. (Pubitemid 38040720)
17. Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:189-194 (Pubitemid 351183307)